The anti-MET monoclonal antibody emibetuzumab exhibited the greatest antitumor activity in HCC when combined with ramucirumab and had an excellent safety profile169 and for HCC with high MET expression there was an almost 3-fold increase in PFS (8.1 vs. 2.8 months) relative to those with low MET expression, suggesting the potential for further biomarker-driven clinical trials. This evidence concerns the gene MET and hepatocellular carcinoma.